- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NICE Comes Back With a List of 40 Expensive Drugs to Be Reassessed
The cost-value discussion in oncology continues in Europe as NICE lists 40 drugs that it plans to reassess in terms of cost versus patient benefit.
More than 40 cancer drugs being paid for out of the government’s Cancer Drugs Fund are to be reassessed to decide if they are worth the money.
Drugs such as Kadcyla, the new Roche offering for advanced breast cancer costing £90,000 a patient, and Avastin, for breast and bowel cancer, could be dropped from the list, so new patients will not be able to get them through the NHS unless the companies lower their prices. Existing patients will continue to get them. Ten new drugs will also be evaluated.
All the cancer drugs in the fund have been turned down for general NHS use by the National Institute for Health and Care Excellence (Nice), which has said the benefit they offer patients is not enough to justify the high price asked by manufacturers.
Read the complete article: http://bit.ly/1uqBjNp
Source: The Guardian
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
